Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

GlaxoSmithKline PLC (NYSE:GSK)

38.72
Delayed Data
As of Jan 20
 -0.03 / -0.08%
Today’s Change
37.20
Today|||52-Week Range
45.58
+0.55%
Year-to-Date
Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson
Jan 21 / MotleyFool.com - Paid Partner Content
Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?
Jan 13 / MotleyFool.com - Paid Partner Content
5 Drugs That Are Way Cheaper in Canada
Jan 21 / MotleyFool.com - Paid Partner Content
4 Signs Glaxo's Turnaround Is Taking Hold
Jan 13 / MotleyFool.com - Paid Partner Content
Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
Jan 20 / Zacks.com - Paid Partner Content
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
Jan 11 / Zacks.com - Paid Partner Content
Frontrunning: January 20
Jan 20 / Investing Channel - Paid Partner Content
3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock
Jan 10 / MotleyFool.com - Paid Partner Content
Flood of News Presents Buying Opportunity
Jan 17 / GuruFocus News - Paid Partner Content
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
Jan 09 / Zacks.com - Paid Partner Content